Ueda Shinichiro

写真a

Title

Professor

Researcher Number(JSPS Kakenhi)

80285105
To the head of this page.▲

Current Affiliation Organization 【 display / non-display 】

  • Duty   University of the Ryukyus   Graduate School of Medicine   Professor  

To the head of this page.▲

Academic degree 【 display / non-display 】

  • Yokohama City University -  Doctor of Medicine

To the head of this page.▲

External Career 【 display / non-display 】

  • 2001.12
    　
    　

    University of the Ryukyus, Graduate School of Medicine, Professor  

To the head of this page.▲

Research Interests 【 display / non-display 】

  • ヒト血管内皮機能

  • 平滑筋機能,心血管薬薬効評価のための代替エンドポイントの開発,降圧利尿薬ランダム化臨床試験,代謝症候群における血管機能

  • インスリン感受性への治療介入と評価

To the head of this page.▲

Published Papers 【 display / non-display 】

  • Association between contrast-induced nephrotoxicity and contrast enhanced computed tomography followed by endoscopic retrograde cholangiopancreatography.

    Shinoura S, Tokushige A, Chinen K, Mori H, Kato S, Ueda S

    European journal of radiology ( European Journal of Radiology )  129   109074 - 109074   2020.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    PURPOSE: To determine if endoscopic retrograde cholangiopancreatography (ERCP) performed within 72 h after contrast enhanced computed tomography (CECT) increases contrast-induced nephrotoxicity (CIN) risk in patients with abdominal complaints. METHOD: This single-center retrospective cohort study included consecutive adult patients with abdominal complaints who underwent CECT between October 1, 2016, and June 30, 2019 at an emergency department (ED). CIN was diagnosed based on serum creatinine (SCr) level >0.5 mg/dL within 72 h after CECT or that increased >25 % compared to pre-CECT level. Logistic regression analysis was performed to determine independent risk factors for CIN, including age, sex, body mass index, comorbidities, medication, pre-CECT SCr level >1.5 mg/dL, and ERCP performed within 72 h after CECT. For persistent CIN, SCr level was obtained after 3 months at the earliest and compared to data obtained within 72 h after ERCP and CECT. RESULTS: Of 1457 patients with CECT, 90 (6.2 %) underwent ERCP within 72 h after CECT and 93 (6.4 %) developed CIN. Multivariate analysis revealed that ERCP performed within 72 h after CECT (odds ratio, 3.31; 95 % confidence interval, 1.74, 6.29; p < 0.001) and pre-CECT SCr level >1.5 mg/dL (odds ratio, 9.86; 95 % confidence interval, 5.08, 19.2; p < 0.001) were independent risk factors for CIN. Of 93 patients with CIN, 10 (11 %) had persistent CIN. No specific factors were correlated with persistent CIN in the 3-month time frame. CONCLUSION: ERCP performed within 72 h after CECT and pre-CECT SCr level >1.5 mg/dL are associated with CIN development.

    • Access this article
      DOI
    • Search related information
      PubMed

  • Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A.

    Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Iwamoto A, Kajikawa M, Matsumoto T, Oda N, Kishimoto S, Matsui S, Hashimoto H, Takaeko Y, Yamaji T, Harada T, Han Y, Aibara Y, Mohamad Yusoff F, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Tomiyama H, Takase B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A, Higashi Y

    Hypertension research : official journal of the Japanese Society of Hypertension ( Hypertension Research )  43 ( 8 ) 781 - 790   2020.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

  • Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).

    Tanaka A, Hisauchi I, Taguchi I, Sezai A, Toyoda S, Tomiyama H, Sata M, Ueda S, Oyama JI, Kitakaze M, Murohara T, Node K, CANDLE Trial Investigators.

    ESC heart failure ( ESC Heart Failure )  7 ( 4 ) 1585 - 1594   2020.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

  • Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.

    Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S

    Cardiovascular diabetology ( Cardiovascular Diabetology )  19 ( 1 ) 89   2020.06 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

  • Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial.

    Tanaka A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima KR, Takamura T, Taguchi I, Hisauchi I, Toyoda S, Matsuzawa Y, Tomiyama H, Yamaoka-Tojo M, Ueda S, Higashi Y, Node K

    Journal of diabetes investigation ( Journal of Diabetes Investigation )    2020.06 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    AIMS/INTRODUCTION: Recent clinical trials on sodium-glucose cotransporter 2 inhibitors showed improved outcomes in patients with type 2 diabetes at a high risk of cardiovascular events. However, the underlying effects on endothelial function remain unclear. MATERIALS AND METHODS: The effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized (EMBLEM) trial in patients with type 2 diabetes and cardiovascular disease showed empagliflozin treatment for 24 weeks had no effect on peripheral endothelial function measured by reactive hyperemia peripheral arterial tonometry. This post-hoc analysis of the EMBLEM trial included a detailed evaluation of the effects of empagliflozin on peripheral endothelial function in order to elucidate the clinical characteristics of responders or non-responders to treatment. RESULTS: Of the 47 patients randomized into the empagliflozin group, 21 (44.7%) showed an increase in the reactive hyperemia index (RHI) after 24 weeks of intervention, with no apparent difference in the clinical characteristics between patients whose RHI either increased (at least >0) or did not increase. There was also no obvious difference between the treatment groups in the proportion of patients who had a clinically meaningful change (≥15%) in log-transformed RHI. No correlation was found between changes in RHI and clinical variables, such as vital signs and laboratory parameters. CONCLUSIONS: Treatment with empagliflozin for 24 weeks in patients with type 2 diabetes and cardiovascular disease did not affect peripheral endothelial function, and was not related to changes in clinical variables, including glycemic parameters. These findings suggest that the actions of sodium-glucose cotransporter 2 inhibitors other than direct improvement in peripheral endothelial function were responsible, at least in the early phase, for the clinical benefits found in recent cardiovascular outcome trials.

    • Access this article
      DOI
    • Search related information
      PubMed

display all >>

To the head of this page.▲

Other Papers 【 display / non-display 】

  • 5. Pit Fall of Clinical Trials for Pharmaceuticals From the Standpoint of Clinical Pharmacology. Trials, Whom is it for ?

    UEDA Shinichiro

    Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics ( The Japanese Society of Clinical Pharmacology and Therapeutics )  50 ( 3 ) 125 - 129   2019

     

    DOI

  • 慢性疾患レジストリで橋をかける産官学そして患者 RCT on Registry,品質管理,標準化 慢性疾患レジストリと臨床試験実施における活用,RCT on registry

    植田 真一郎, 徳重 明央, 比嘉 真由美, 藤田 優子, 宇根 かおり, 池原 由美

    臨床薬理 ( (一社)日本臨床薬理学会 )  48 ( Suppl. ) S208 - S208   2017.11

     

  • 降圧薬投与下での内皮機能と発症前血管損傷の進行 FMD-J多施設共同前向き研究の結果(Endothelial Function and the Progression of Preclinical Vascular Damages Under Antihypertensive Medication: The Results of FMD-J Multi-Center Prospective Study)

    冨山 博史, 山科 章, 前村 浩二, 木庭 新治, 山崎 力, 佐田 政隆, 石津 智子, 伊藤 浩, 竹本 恭彦, 東 幸仁, 鈴木 亨, 大屋 祐輔, 植田 真一郎, 苅尾 七臣, 古川 泰司, 高瀬 凡平, 井上 晃男, 野出 孝一, 松本 知沙, 石橋 豊

    日本循環器学会学術集会抄録集 ( (一社)日本循環器学会 )  81回   LBCSP1 - 6   2017.03  [Refereed]

     

  • 臨床研究教育プログラム参加医師の背景分析に基づくキャリアパスの提案

    池原 由美, 大城 絢子, 齋藤 麻衣子, 植田 真一郎

    臨床薬理 ( (一社)日本臨床薬理学会 )  47 ( Suppl. ) S286 - S286   2016.10  [Refereed]

     

  • 臨床現場を反映した臨床研究教育プログラムにおけるADDIEモデルの適用結果と適合性の検証

    大城 絢子, 池原 由美, 植田 真一郎

    医学教育 ( (一社)日本医学教育学会 )  47 ( Suppl. ) 207 - 207   2016.07  [Refereed]

     

display all >>

To the head of this page.▲

Presentations 【 display / non-display 】

To the head of this page.▲

Other External funds 【 display / non-display 】

  • Project Year: 2020.04  -  2021.03 

    Offer Organization: AMED

To the head of this page.▲